Skip to main content
Carisma Therapeutics Inc. logo

Carisma Therapeutics Inc. — Investor Relations & Filings

Ticker · CARM ISIN · US14216R1014 LEI · 549300DGKHONOZQIY116 US Manufacturing
Open in API
Filings indexed 853 across all filing types
Latest filing 2025-01-30 Director's Dealing
Country US United States of America
Listing US CARM

About Carisma Therapeutics Inc.

https://sesenbio.com/

Carisma Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of engineered macrophage-based therapeutics. The company's proprietary cell therapy platform is centered on Chimeric Antigen Receptor Macrophages (CAR-M) and CAR-Monocytes. This approach is designed to leverage the unique abilities of macrophages to infiltrate solid tumors, overcome the immunosuppressive tumor microenvironment, and stimulate a broad anti-tumor response. Carisma's pipeline is focused on developing treatments for cancer and other serious disorders, including fibrosis.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2025-01-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-01-30 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 13, 2025. It announces that the company will be posting an updated corporate presentation on its website. The content mainly discusses upcoming clinical trials and forward-looking statements about the company's plans. There are no financial statements or detailed financial data included. The document is a regulatory announcement about other events and updates rather than a full financial report or presentation itself. It is not an earnings release, annual report, or interim report. The document is not a certification or insider trading report. Given the nature of the filing (Form 8-K) and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2025-01-13 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 6, 2025, by Carisma Therapeutics Inc. The key content is a notice from Nasdaq regarding the company's non-compliance with the minimum bid price rule, which is a notification of deficiency related to potential delisting. The document discusses the compliance period, possible transfer to Nasdaq Capital Market, and the appeal process. This is a regulatory announcement about the company's listing status and potential delisting, not a full financial report or earnings release. The document is a formal notice of delisting risk, fitting the definition of a Delisting Announcement (DLST). The document length (7071 characters) supports it being a full announcement rather than a brief report publication notice or certification. Therefore, the correct classification is DLST with high confidence.
2025-01-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-01-02 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content focuses on the appointment of a new interim Vice President of Finance and principal financial officer, including details about a master services agreement and the individual's background. There are no financial statements or earnings data presented. The primary subject is a management change announcement. Therefore, this document fits the category of Board/Management Information (MANG). The document length is over 6000 characters, indicating it is not a brief announcement but a full report of the management change event.
2024-12-26 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.